The upcoming presentations will feature eight abstracts, six of which are slated for the EDCC event starting October 6, with two additional reports scheduled for the ESMO Congress in late October. The research spans critical areas of diagnostics, including the efficiency of Cancer Signal Origin guided workups and the performance of the Galleri test across varying racial and ethnic groups. Other key data points include evidence on the preclinical detection window and a reduction in emergency cancer presentations following annual screenings.
GRAIL to Unveil New Galleri Cancer Detection Data at EDCC and ESMO
GRAIL is set to present findings from its NHS-Galleri and PATHFINDER 2 trials at two major medical summits, the Early Detection of Cancer Conference in Edinburgh and the ESMO Congress in Madrid, aiming to further validate the clinical utility of its multi-cancer early detection technology in diverse populations.
Josh Ofman, CEO of GRAIL, stated that ongoing analyses continue to support the integration of these tests into routine care. The findings highlight the company's focus on identifying cancers in early stages before symptoms emerge, a priority for improving long-term survival. The data also addresses the diagnostic journey, specifically looking at how blood-based tests fit into broader clinical practice. The results are expected to bolster the existing evidence base for the company's methylation-based platform, which currently screens for over 50 cancer types.
Comments (0)
No comments yet. Be the first!